



March 23, 2020

Dear Valued Customer,

Over the last few weeks, like many of you, we have been monitoring the evolving coronavirus (COVID-19) pandemic. As COVID-19 cases continue to increase in Australia, we are experiencing an increased volume of requests from hospitals nationally for additional resources. This letter is intended to help clarify our commitment to continuing supply of Mallinckrodt's products in the foreseeable future, in light of the apparently increasing demand in Australia.

After review of our end-to-end supply chain, including collaboration with our suppliers, Mallinckrodt does not currently anticipate any significant disruption to our manufacturing and/or distribution capabilities resulting from the COVID-19 situation. We are confident that our existing supplies of products together with our forward orders due over the coming months, will ensure that there is no likely shortage of supply to our existing customers. We are continuing to monitor the situation as it evolves.

We appreciate that the coming weeks and months may also see an increased demand for delivery devices and, while we are committed to providing a minimally interrupted service to the healthcare system, we are operating with finite resources at our disposal. We are working with our global counterparts to increase our resources at this time and will keep our customers informed of additional capacity and other developments as the information becomes available.

During this time, as per existing contractual agreements, customers should not relocate devices outside of the current facilities, as proper relocation procedures need to be followed to ensure the device integrity and patient safety. If you are contacted to provide a device to another facility, please call us so we can work with you to make appropriate arrangements.

On behalf of Mallinckrodt Pharmaceuticals, we thank you for your ongoing support and understanding as we continue to work in partnership with you to get through this pandemic. If you have further questions, I encourage you to reach out to your Mallinckrodt Critical Care Business Manager on **1300 198 565**.

Mallinckrodt Pharmaceuticals advises prescribers that any use of a medicine outside its TGA approved indication must be under the TGA Special Access Scheme (SAS) which provides access to non-approved therapeutic goods / indications. Details of the SAS process are provided at <https://www.tga.gov.au/form/special-access-scheme>.

Best regards,

Steven J. Skorobogaty
General Manager – Australia & New Zealand
Ikaria Australia Pty Ltd, a Mallinckrodt Pharmaceuticals Company